Clinical trial
A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in…
NCT00233870 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00233870 |
|---|---|
| Title | A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. |
| Official title | Special Survey in Long-Term Use of Fabrazyme |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | Agalsidase beta (recombinant form) |
| Enrollment | 405 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Oct 6, 2005 |
| Last update posted | May 8, 2015 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: